Cited by 31Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration

Open access
Wheeler, Jeanna M., McMillan, Pamela J., Hawk, Michele, Iba, Michiyo, Robinson, Linda, Xu, George J., Dombroski, Beth A., Jeong, Doori +9 more·2015·Acta Neuropathologica Communications

Abstract

INTRODUCTION: Accumulation of insoluble conformationally altered hyperphosphorylated tau occurs as part of the pathogenic process in Alzheimer's disease (AD) and other tauopathies. In most AD subjects, wild-type (WT) tau aggregates and accumulates in neurofibrillary tangles and dystrophic neurites in the brain; however, in some familial tauopathy disorders, mutations in the gene encoding tau cause disease. RESULTS: We generated a mouse model, Tau4RTg2652, that expresses high levels of normal human tau in neurons resulting in the early stages of tau pathology. In this model, over expression of WT human tau drives pre-tangle pathology in young mice resulting in behavioral deficits. These changes occur at a relatively young age and recapitulate early pre-tangle stages of tau pathology associated with AD and mild cognitive impairment. Several features distinguish the Tau4RTg2652 model of tauopathy from previously described tau transgenic mice. Unlike other mouse models where behavioral and neuropathologic changes are induced by transgenic tau harboring MAPT mutations pathogenic for frontotemporal lobar degeneration (FTLD), the mice described here express the normal tau sequence. CONCLUSIONS: Features of Tau4RTg2652 mice distinguishing them from other established wild type tau overexpressing mice include very early phenotypic manifestations, non-progressive tau pathology, abundant pre-tangle and phosphorylated tau, sparse oligomeric tau species, undetectable fibrillar tau pathology, stability of tau transgene copy number/expression, and normal lifespan. These results suggest that Tau4RTg2652 animals may facilitate studies of tauopathy target engagement where WT tau is driving tauopathy phenotypes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40478-015-0210-6

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tg2652 mice exhibit early accumulation of pTau but live a normal life span without gliosis or neuronal loss.

    “Tg2652 mice exhibit early accumulation of pTau but live a normal life span without gliosis or neuronal loss (Wheeler et al. 2015).”

    From Perineuronal net deglycosylation associates with tauopathy‐induced gliosis and neurodegeneration (2024) · cites this paper as Wheeler et al. 2015

    The Results (Fig. 1) show phosphorylated tau by three months and report an approximately normal lifespan. The Discussion reports no evidence of focal or widespread neuronal loss. Our copy does not establish the claimed absence of gliosis. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 26

  1. [1]Arriagada PV Growdon JH Hedley-Whyte ET Hyman BT Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease Neurology 1992 42 631 639 10.1212/WNL.42.3.631 1549228 · DOI · Paper page
  2. [3]Braak H Thal DR Ghebremedhin E Del Tredici K Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years J Neuropathol Exp Neurol 2011 70 960 969 10.1097/NEN.0b013e318232a379 22002422 · DOI · Paper page
  3. [4]Haroutunian V Davies P Vianna C Buxbaum JD Purohit DP Tau protein abnormalities associated with the progression of alzheimer disease type dementia Neurobiol Aging 2007 28 1 7 10.1016/j.neurobiolaging.2005.11.001 16343696 · DOI · Paper page
  4. [5]Ballatore C Lee VM Trojanowski JQ Tau-mediated neurodegeneration in Alzheimer's disease and related disorders Nat Rev Neurosci 2007 8 663 672 10.1038/nrn2194 17684513 · DOI · Paper page
  5. [6]Buee L Troquier L Burnouf S Belarbi K Van der Jeugd A Ahmed T Fernandez-Gomez F Caillierez R Grosjean ME Begard S From tau phosphorylation to tau aggregation: what about neuronal death? Biochem Soc Trans 2010 38 967 972 10.1042/BST0380967 20658986 · DOI
  6. [7]Gotz J Xia D Leinenga G Chew YL Nicholas H What Renders TAU Toxic Frontiers in Neurology 2013 4 72 10.3389/fneur.2013.00072 23772223 PMC3677143 · DOI
  7. [8]Mandelkow EM Mandelkow E Biochemistry and cell biology of tau protein in neurofibrillary degeneration Cold Spring Harb Perspect Med 2012 2 a006247 10.1101/cshperspect.a006247 22762014 PMC3385935 · DOI
  8. [10]Weaver CL Espinoza M Kress Y Davies P Conformational change as one of the earliest alterations of tau in Alzheimer's disease Neurobiol Aging 2000 21 719 727 10.1016/S0197-4580(00)00157-3 11016541 · DOI · Paper page
  9. [11]Wolozin BL Pruchnicki A Dickson DW Davies P A neuronal antigen in the brains of Alzheimer patients Science 1986 232 648 650 10.1126/science.3083509 3083509 · DOI
  10. [12]Greenberg SG Davies P Schein JD Binder LI Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau J Biol Chem 1992 267 564 569 1370450
  11. [13]Ward SM Himmelstein DS Lancia JK Fu Y Patterson KR Binder LI TOC1: characterization of a selective oligomeric tau antibody J Alzheimers Dis 2013 37 593 602 23979027 PMC4791958
  12. [14]Ishihara T Hong M Zhang B Nakagawa Y Lee MK Trojanowski JQ Lee VM Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform Neuron 1999 24 751 762 10.1016/S0896-6273(00)81127-7 10595524 · DOI · Paper page
  13. [15]Seki T Spurr N Obata F Goyert S Goodfellow P Silver J The human Thy-1 gene: structure and chromosomal location Proc Natl Acad Sci U S A 1985 82 6657 6661 10.1073/pnas.82.19.6657 2864690 PMC391269 · DOI
  14. [16]Guthrie CR Schellenberg GD Kraemer BC SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans Hum Mol Genet 2009 18 1825 1838 10.1093/hmg/ddp099 19273536 PMC2722225 · DOI
  15. [17]Sun AY Nguyen XV Bing GY Comparative analysis of an improved thioflavin-S stain, Gallyas silver stain, and immunohistochemistry for neurofibrillary tangle demonstration on the same sections Journal of Histochemistry & Cytochemistry 2002 50 463 472 10.1177/002215540205000403 11897799 · DOI
  16. [18]Pluchino S Quattrini A Brambilla E Gritti A Salani G Dina G Galli R Del Carro U Amadio S Bergami A Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis Nature 2003 422 688 694 10.1038/nature01552 12700753 · DOI
  17. [19]Ward SM Himmelstein DS Lancia JK Binder LI Tau oligomers and tau toxicity in neurodegenerative disease Biochem Soc Trans 2012 40 667 671 10.1042/BST20120134 22817713 PMC3704193 · DOI
  18. [20]Ward SM Himmelstein DS Ren Y Fu Y Yu XW Roberts K Binder LI Sahara N TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy Neurobiol Dis 2014 67 37 48 10.1016/j.nbd.2014.03.002 24631720 PMC4055868 · DOI
  19. [21]Barnes CA Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat Journal of Comparative and Physiological Psychology 1979 93 74 104 10.1037/h0077579 221551 · DOI · Paper page
  20. [22]O'Leary TP Brown RE Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease Behav Brain Res 2009 201 120 127 10.1016/j.bbr.2009.01.039 19428625 · DOI
  21. [24]Jeganathan S vonBergen M Brutlach H Steinhoff HJ Mandelkow E Global hairpin folding of tau in solution Biochemistry 2006 45 2283 2293 10.1021/bi0521543 16475817 · DOI · Paper page
  22. [25]Kanaan NM Morfini G Pigino G LaPointe NE Andreadis A Song Y Leitman E Binder LI Brady ST Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport Neurobiol Aging 2012 33 826 e815 830 21794954 PMC3272324
  23. [26]Probst A Gotz J Wiederhold KH Tolnay M Mistl C Jaton AL Hong M Ishihara T Lee VM Trojanowski JQ Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein Acta Neuropathol 2000 99 469 481 10.1007/s004010051148 10805089 · DOI
  24. [27]Spittaels K Vandenhaute C Vandorpe J Bruynseels K Vandezande K Laenen I Geerts H Mercken M Sciot R Vanlommel A Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein American Journal of Pathology 1999 155 2153 2165 10.1016/S0002-9440(10)65533-2 10595944 PMC1866931 · DOI
  25. [29]Andorfer C Kress Y Espinoza M de Silva R Tucker KL Barde YA Duff K Davies P Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms J Neurochem 2003 86 582 590 10.1046/j.1471-4159.2003.01879.x 12859672 · DOI · Paper page
  26. [31]Gotz J Ittner LM Animal models of Alzheimer's disease and frontotemporal dementia Nat Rev Neurosci 2008 9 532 544 10.1038/nrn2420 18568014 · DOI · Paper page

Cited by

Sorted by citations

Authors
Wheeler, J. M., McMillan, P. J., Hawk, M., Iba, M., Robinson, L., Xu, G. J., Dombroski, B. A., Jeong, D., Dichter, M. A., Juul, H., Loomis, E., Raskind, M., Leverenz, J. B., Trojanowski, J. Q., Lee, V. M. Y., Schellenberg, G. D., & Kraemer, B. C.
Affiliations
  • VA Puget Sound Health Care System (US)
  • University of Washington (US)
  • University of Pennsylvania (US)
  • Cleveland Clinic (US)
Corresponding author
  • Schellenberg, Gerard D.
  • Kraemer, Brian C.
Venue
Acta Neuropathologica Communications
Published
2015-06-04
Volume
3
Issue
1
Pages
33-33
ISSN
2051-5960 (ISSN-L)
OpenAlex
W1924863490
Cited by
31
References
5
Citations by year
2026: 3 · 2025: 5 · 2024: 3 · 2023: 5 · 2021: 3 · 2020: 3 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 2
FWCI
1.72
Type
journal article
Language
en
Open access
Locations
  • Acta Neuropathologica Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs (I01 BX002619)
  • University of Pennsylvania
  • University of Washington
  • National Institute on Aging (P01AG017586, AG-017586, P50AG005136)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
tauopathy, Alzheimer's disease, neurofibrillary tangles, hyperphosphorylated tau, cognitive impairment, transgenic mouse model, tau oligomers, tau phosphorylation, frontotemporal lobar degeneration, target engagement
MeSH terms
Age Factors, Analysis of Variance, Animals, Brain, Cognition Disorders, Electroencephalography, Exploratory Behavior, Humans, Mice, Inbred C57BL, Mice, Transgenic, Motor Activity, Neurofibrillary Tangles, tau Proteins, Disease Progression, Maze Learning, Tauopathies, Mice, Muscle Strength, DNA Copy Number Variations

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review